MX2019014090A - Métodos para el tratamiento de la reservoritis crónica. - Google Patents

Métodos para el tratamiento de la reservoritis crónica.

Info

Publication number
MX2019014090A
MX2019014090A MX2019014090A MX2019014090A MX2019014090A MX 2019014090 A MX2019014090 A MX 2019014090A MX 2019014090 A MX2019014090 A MX 2019014090A MX 2019014090 A MX2019014090 A MX 2019014090A MX 2019014090 A MX2019014090 A MX 2019014090A
Authority
MX
Mexico
Prior art keywords
treatment
methods
chronic pouchitis
pouchitis
chronic
Prior art date
Application number
MX2019014090A
Other languages
English (en)
Spanish (es)
Inventor
Maria Rosario
Michael David Laurence Smyth
Hauw Tan
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MX2019014090A publication Critical patent/MX2019014090A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019014090A 2017-05-26 2018-05-26 Métodos para el tratamiento de la reservoritis crónica. MX2019014090A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511832P 2017-05-26 2017-05-26
PCT/IB2018/053760 WO2018215995A1 (en) 2017-05-26 2018-05-26 Methods for the treatment of chronic pouchitis

Publications (1)

Publication Number Publication Date
MX2019014090A true MX2019014090A (es) 2021-01-08

Family

ID=64395342

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014090A MX2019014090A (es) 2017-05-26 2018-05-26 Métodos para el tratamiento de la reservoritis crónica.

Country Status (10)

Country Link
US (2) US20200087401A1 (enExample)
EP (1) EP3630184A4 (enExample)
JP (2) JP7497159B2 (enExample)
KR (1) KR20200011457A (enExample)
AU (1) AU2018274749B2 (enExample)
BR (1) BR112019024875A2 (enExample)
CA (1) CA3065000A1 (enExample)
IL (1) IL270819A (enExample)
MX (1) MX2019014090A (enExample)
WO (1) WO2018215995A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
WO2023163883A1 (en) * 2022-02-22 2023-08-31 First Wave BioPharma, Inc. Compositions and methods for treating pouchitis
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551593B1 (en) * 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
JP6904905B2 (ja) * 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測

Also Published As

Publication number Publication date
US20200087401A1 (en) 2020-03-19
KR20200011457A (ko) 2020-02-03
JP2020521761A (ja) 2020-07-27
BR112019024875A2 (pt) 2020-06-16
IL270819A (en) 2020-01-30
EP3630184A4 (en) 2021-03-17
JP7497159B2 (ja) 2024-06-10
CA3065000A1 (en) 2018-11-29
RU2019143659A (ru) 2021-06-28
US20230043949A1 (en) 2023-02-09
AU2018274749A1 (en) 2019-12-19
RU2019143659A3 (enExample) 2021-10-08
AU2018274749B2 (en) 2025-05-22
WO2018215995A1 (en) 2018-11-29
JP2024069230A (ja) 2024-05-21
EP3630184A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
ZA202107931B (en) Anti-tau antibodies and methods of use
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
MX2022013524A (es) Anticuerpos neutralizantes para el virus de inmunodeficiencia humana.
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2022001105A (es) Anticuerpos anti tigit.
PH12016501894A1 (en) Anti-ox40 antibodies and methods of use
NZ731467A (en) Anti-tim3 antibodies and methods of use
PH12016501644B1 (en) Binding proteins and methods of use thereof
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
GB2541571A (en) Pharmaceutical compositions
PH12015502788A1 (en) Antibody formulations and methods
EA202090683A3 (ru) Способы и композиции для лечения рака
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
ZA201703510B (en) Antibodies, uses & methods
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
NZ744340A (en) Anti-jagged1 antibodies and methods of use